Noting that clinical trial participation in patients with poor performance status is challenging due to protocol restrictions, the panel applauded efforts by the ASCO-Friends of Cancer Research working group, which is taking steps to broaden clinical trial eligibility and recommended that, whenever feasible, these patients be considered for clinical trial participation whether or not their tumor harbors a BRAF mutation (see Fig. 4). The gene discussed is BRAF; the disease is cancer.